Satellite Symposia
Thursday June 20
| 08:00 – 09:00 Room Escudo |
Breakfast with the expert CHEMSEX: A NEW CHALLENGE IN MENTAL HEALTH AND INFECTIONS Sponsored by MSD Chair: Pablo Vega, Instituto de Adicciones. Madrid Salud. España. Speakers: INVOLVED SUBSTANCES AND PSYCHOPATHOLOGICAL ASPECTS Helen Dolengevich, Hospital Universitario del Henares. Madrid, España. IMPLICATIONS IN INFECTIOUS DISEASES Ignacio Pérez Valero, Unidad de Enfermedades Infecciosas. Hospital U. La Paz, Madrid. España. DISCUSSION AND CONCLUSIONS |
| 13:30 – 14:30 Room Doblón |
Symposium HOW ELVANSE CAN REDUCE THE RISK OF ADDICTION IN ADHD PATIENTS Sponsored by Takeda Chair: Jose R. Gutierrez Casares, Servicio Extremeño de Salud. España. Speaker: Carlos Roncero, Complejo Asistencial Universitario de Salamanca, Universidad de Salamanca. España. Q&A |
| 18:00 – 19:30 Room Doblón |
Symposium THE IMPORTANCE OF RECEIVERS IN THE MANAGEMENT OF THE PATIENT WITH BIPOLAR DISORDER AND SUBSTANCE USE DISORDER Sponsored by Lundbeck Speakers: RECEIVERS INVOLVED IN BIPOLAR DISORDER AND SUBSTANCE USE DISORDER Philip Gorwood, Sainte-Anne Hospital, Paris Descartes University. Paris, France. FROM NEUROBIOLOGY TO CLINICAL PRACTICE: CONSIDERATIONS ON BIPOLAR DISORDER AND EACH TYPE OF SUBSTANCE Adrián Neyra, Hosp. Universitario Gran Canaria Doctor Negrin. Gran Canaria. España. RECOMMENDATIONS FOR THE USE OF ASENAPINE IN DUAL PATIENT Antoni Benabarre, Institut Clínic de Neurociències. Hospital Clínic de Barcelona. Universidad de Barcelona. Barcelona, España. |
| 18:00 – 19:30 Room Jardín |
Symposium DUAL DISORDERS AND CLOZAPINE, A CURRENT DEBATE Sponsored by Adamed Chair: Miquel Bernardo, Hospital Clínic. Universitat De Barcelona. España. Speakers: DUAL PSYCHOSIS. HOW TO IMPROVE RESULTS? Néstor Szerman, Servicio Salud Mental Retiro, Hospital General Universitario Gregorio Marañón. Madrid, España. HOW DO WE TREAT PATIENTS WITH DUAL DISORDERS? THERE ARE DIFFERENT PROBLEMS OR CHALLENGES IN THIS ASPECT Marta Torrens, Institut de Neuropsiquiatria I Addiccions-Parc de Salut Mar, Universitat Autònom. Barcelona, España. WHY CAN CLOZAPINE BE ADDITIONALLY INTERESTED IN DUAL DISORDERS? Luis San, Salud Mental Parc Sanitari de Sant Joan de Déu. Barcelona, España. |
Friday June 21
| 12:00 – 13:30 Room Tapices |
Symposium YOUNG PEOPLE AND PSYCHOSIS, WHAT CAN WE DO? Sponsored by Otsuka – Lundbeck Speakers: EARLY INTERVENTION IN YOUNG PEOPLE, THEORY OR REALITY? Celso Arango, Hospital General Universitario Gregorio Marañón. Madrid, España. SCHIZOPHRENIA AND CONSUMPTION, HOW TO ACT? Giovanni Martinotti, Università degli Studi G. d’Annunzio Chieti e Pescara. Italy. Sergio Arques, Hospital Universitario Arnau de Vilanova. Valencia, España. |
| 12:00 – 13:30 Room Jardín |
Symposium ONE MORE ANTIDEPRESSANT FOR DUAL DEPRESSION, OR A VERY SPECIAL ONE? Sponsored by Exeltis Chair: Jon-Kar Zubieta, University of Utah, USA. Speakers: NEUROBIOLOGY OF PLACEBO EFFECTS IN DEPRESSION Jon-Kar Zubieta, University of Utah, USA. TIANEPTINA: IS IT DIFFERENT? Néstor Szerman, Servicio Salud Mental Retiro, Hospital General Universitario Gregorio Marañón. Madrid, España. TIANEPTINA IN DUAL DEPRESSION Francisco Arias, Hospital Universitario 12 de Octubre. Madrid, España. |
| 12:00 – 13:30 Room Comendador |
Symposium ELIMINATION OF HEPATITIS C: A RESPONSIBILITY OF ALL Sponsored by Abbvie Chair: Pablo Vega, Instituto de Adicciones. Madrid Salud. España. Speakers: WHEN HEPATITIS C IS A PUBLIC HEALTH PROBLEM Joan Colom, Programa de Prevenció, Control i Atenció al VIH, les ITS i les Hepatitis Víriques. Agència de Salut Pública de Catalunya. España. SMALL ACTIONS, GREAT RESULTS: ELIMINATING HEPATITIS C IN THE UCA OF CIUDAD REAL Mª del Mar Sánchez, Comisión Nacional PAIME. PAIME de Castilla La Mancha. España. ELIMINATION OF HCV: THE RELEVANCE OF THE PATIENT WITH DUAL DISORDERS Carlos Roncero, Complejo Asistencial Universitario de Salamanca, Universidad de Salamanca. España. |
| 12:00 – 13:30 Room Escudo |
Symposium A NEW NUTRITIONAL APPROACH FOR MENTAL HEALTH Sponsored by Cantabria Labs/Nutrición Médica Chair: Jerónimo Sáiz, Hospital Ramón y Cajal Madrid, España. Speakers: MICROBIOTA AND ITS IMPLICATION IN MENTAL HEALTH Vicent Balanzá, Hospital Universitario y Politécnico La Fe. Valencia, España. COGNITION, NUTRITION AND PREVENTION. ALL OF THEM OR THE SUM OF PARTS Pedro Gil, Hospital Clínico San Carlos. Madrid, España. L- ACETYL CARNITINE IN THE TREATMENT OF DEPRESSIVE DISORDERS Manuel Bousoño, Universidad de Oviedo. España. |
| 17:30 – 19:00 Room Tapices |
Symposium DOUBTS TO RESOLVE: DUAL DEPRESSION, ANY ANTIDEPRESSANT? Sponsored by Lundbeck Speakers: DEPRESSION AND SUBSTANCE ABUSE Marta Torrens, Institut de Neuropsiquiatria I Addiccions-Parc de Salut Mar, Universitat Autònom. Barcelona, España. WHAT DO ANTIDEPRESSANT TREATMENT OFFER AT TODAY’S DATE? Pedro Iborra, Centro Psiquiatría Lucentum. Alicante, España. NEW RESEARCH FIELDS WITH VORTIOXETINE Ignacio Basurte, Hospital General Universitario Gregorio Marañón. Madrid, España. |
| 17:30 – 19:00 Room Doblón |
Symposium CARIPRAZINE: A PROMISING NEW ANTIPSYCHOTIC IN DUAL DISORDERS Sponsored by Casen Recordati Chair: Carlos Roncero, Complejo Asistencial Universitario de Salamanca, Universidad de Salamanca. España. Speakers: CARIPRAZINE AND DUAL DISORDERS. A PROMISING ALLIANCE Cecilio Álamo, Universidad de Alcalá. Alcalá de Henares. Madrid, España. CARIPRAZINE. A NEW TREATMENT TO FACE THE CHALLENGES OF SCHIZOPHRENIA Miquel Bernardo, Hospital Clínic. Universitat De Barcelona. España. WHAT PLACE DOES CARIPRAZINE HAVE IN THE TREATMENT OF DUAL DIAGNOSIS PATIENTS? Carlos Roncero, Complejo Asistencial Universitario de Salamanca, Universidad de Salamanca. España. |
www.icdd-congress.com
